Hematology

Safety of Guadecitabine Consistent Across Phase 3 Trials in Various Hematologic Malignancies

October 16, 2020

Two phase 3 clinical trials demonstrated consistent safety findings with the expected safety profile of guadecitabine as treatment of 2 patient populations, including patients with previously treated acute myeloid leukemia in ASTRAL-2 and patients with previously treated myelodysplastic syndrome or chronic myelomonocytic leukemia in ASTRAL-3.

Investigational Agent Achieves All Secondary End Points in Phase 3 Study of Hematologic Malignancies

October 12, 2020

Omidubicel as treatment of patients with high-risk hematologic malignancies induced rapid platelet engraftment and a reduction in the number of infections and hospitalizations, meeting all 3 secondary end points of a phase 3 clinical trial.

Encouraging ORR Observed With CLR 131 as CLOVER-1 Heads To Pivotal Stage

September 29, 2020

CLR 131, a phospholipid ether molecule, is showing promising disease control in an ongoing phase 2 study as treatment of patients with relapsed or refractory lymphoplasmacytic lymphoma and Waldenström macroglobulinemia, according to initial study results.